VALCHLOR® (mechlorethamine) gel is an alkylating drug indicated for the topical treatment of Stage IA and IB mycosis fungoides–type cutaneous T-cell lymphoma (MF-CTCL) in patients who have received prior skin-directed therapy

VALCHLOR safety profile1

Local skin reactions were the most common (≥5%) adverse reaction in the clinical study1

  VALCHLOR gel (n=128) Compounded mechlorethamine HCI
  Any grade Moderately severe or severe Any grade Moderately severe
or severe
Dermatitis 56% 23% 58% 17%
Pruritus 20% 4% 16% 2%
Bacterial skin infection 11% 2% 9% 2%
Skin ulceration or blistering 6% 3% 5% 2%
Skin hyperpigmentation 5% 0% 7% 0%
  • Concomitant use of topical corticosteroids was not permitted during the trial1
  • In the pivotal trial, moderately severe or severe skin-related adverse reactions were managed with treatment reduction, suspension, or discontinuation1
  • Similar rates of AR-related treatment discontinuations were observed (22% with VALCHLOR and 18% with compounded mechlorethamine HCl)1

Proactively manage skin reactions with dose modifications1

Dose modifications may help patients continue with their treatment1

Temporarily suspend VALCHLOR gel if patient develops: any grade of skin ulceration, blistering, or moderately severe or severe dermatitis (ie, marked skin redness with edema).

Upon improvement, treatment can be gradually reintroduced into patient's treatment plan1:


VALCHLOR gel once every 3 days when patient improves1


VALCHLOR gel applied once every other day if tolerated after 1 week with improvement1


once-daily application of VALCHLOR gel if tolerated for at least 1 week1

Help your patients continue on treatment by setting expectations and establishing a plan to manage potential skin reactions